Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Tango Therapeutics (NASDAQ: TNGX) said CEO Barbara Weber, M.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST / 12:45pm EST.

The presentation will be streamed live via the Investors > Events & Presentations page on the company's website, and a replay will be archived on the website for 90 days after the event.

Key Figures

Presentation date January 14, 2026 J.P. Morgan Healthcare Conference corporate presentation

Presentation time 9:45am PST / 12:45pm EST Scheduled conference session start time

Webcast replay duration 90 days Replay archived on company website

Share price $8.96 Price prior to conference participation news

52-week range $1.03 – $11.20 52-week low and high for TNGX

Market cap $1,228,255,097 Equity value prior to the announcement

Today’s volume 2,255,536 shares Compared with 20-day average of 2,688,245

Resale shares registered 1,732,101 shares S-3 resale registration filed November 21, 2025

Market Reality Check

$8.52 Last Close

Volume Volume 2,255,536 is below 20-day average 2,688,245 (relative volume 0.84x). normal

Technical Shares at $8.96, trading above 200-day MA of $5.44 and 20% below the 52-week high of $11.20.

Peers on Argus

Peers show mixed moves: AVBP -1.62%, DAWN -0.36%, AVXL -0.50%, IMTX +2.02%, SANA 0.00%, suggesting stock-specific factors for TNGX.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 26	Conference participation	Neutral	+1.8%	Announcement of participation in Piper Sandler healthcare conference with webcast replay.
Nov 12	Conference participation	Neutral	-8.5%	Jefferies healthcare conference fireside chat announcement with webcast access.
Nov 04	Earnings and pipeline	Positive	+0.0%	Q3 2025 profit, cash position, and multiple oncology program updates.
Oct 29	Earnings notice	Neutral	+0.5%	Scheduling notice for Q3 2025 financial results release without conference call.
Oct 23	Equity financing	Negative	-13.1%	Underwritten offering and PIPE totaling about $225M in gross proceeds.

Pattern Detected

Routine conference announcements have produced mixed reactions, while financing news aligned with a negative price move and positive earnings saw little immediate impact.

Recent Company History

Over the last few months, Tango Therapeutics reported a profitable Q3 2025 driven by collaboration revenue and strengthened its balance sheet through approximately $225 million in October 2025 financing. Liquidity disclosures and a detailed Q3 10‑Q highlighted cash of $152.8M as of Sept 30, 2025 and a runway into 2028. At the same time, several conference and participation announcements, including healthcare conferences, generated varied short-term price reactions. Today’s J.P. Morgan conference participation fits within this pattern of ongoing investor outreach rather than a discrete clinical or financial catalyst.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-21

An effective S-3 resale registration dated Nov 21, 2025 covers up to 1,732,101 already issued shares from an October 2025 private placement at $8.66 per share. Future resales under this prospectus will be by a selling stockholder, and Tango will receive no cash proceeds from those transactions.

Market Pulse Summary

This announcement highlights Tango’s upcoming presentation at the J.P. Morgan Healthcare Conference on January 14, 2026, extending a pattern of regular participation in major investor events. Shares traded at $8.96, above the 200-day moving average of $5.44 yet below the $11.20 52-week high, with volume modestly under recent norms. In the background, the company maintains a resale registration for 1,732,101 previously issued shares, and recent financings have extended its reported cash runway into 2028.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:

Elizabeth Hickin
IR@tangotx.com
media@tangotx.com

FAQ

When will Tango Therapeutics (TNGX) present at the J.P. Morgan Healthcare Conference?

Tango will present on January 14, 2026 at 9:45am PST / 12:45pm EST.

Who is presenting for Tango Therapeutics (TNGX) at the January 14, 2026 presentation?

Barbara Weber, M.D., President and Chief Executive Officer, is scheduled to present.

Where can investors watch the Tango Therapeutics (TNGX) live webcast on January 14, 2026?

The live webcast will be available under Investors > Events & Presentations on the company's website.

How long will the Tango Therapeutics (TNGX) presentation replay be available online?

A replay will be archived on the company's website for 90 days following the presentation.

What time is the Tango Therapeutics (TNGX) presentation in Eastern Time?

The presentation is scheduled for 12:45pm Eastern Time on January 14, 2026.